Market Overview

Polycythemia - Pipeline Insight, 2018 Report -


The "Polycythemia
- Pipeline Insight, 2018"
drug pipelines has been added to's

'Polycythemia - Pipeline Insight, 2018' report offers comprehensive
Insight of the pipeline (under development) therapeutics scenario and
growth prospects across Polycythemia development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Polycythemia Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products In Clinical Stage

6. Products In Pre-Clinical And Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

Companies Mentioned

  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Galena Biopharma Inc
  • Gilead Sciences Inc
  • Italfarmaco SpA
  • Karus Therapeutics Ltd
  • Nerviano Medical Sciences Srl
  • Novartis AG

For more information about this drug pipelines report visit

View Comments and Join the Discussion!